Who is sponsoring NCT05882630?

NCT05882630 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT05882630?

Interventions in NCT05882630: Surufatinib,Serplulimab,Etoposide,Carboplatin.

What condition does NCT05882630 study?

NCT05882630 studies Small Cell Lung Cancer.

Is NCT05882630 still recruiting?

NCT05882630 is currently not yet recruiting. Last updated 31 May 2023.

Last reviewed 2023-05-31 · How we verify

NCT05882630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Not yet recruiting Phase 1, PHASE2 Last updated 31 May 2023

What this trial tests

Phase 1, PHASE2 trial testing Surufatinib,Serplulimab,Etoposide,Carboplatin in Small Cell Lung Cancer in 39 participants. Not yet recruiting.

Timeline

1 June 2023

Primary endpoint
1 June 2025

1 June 2026

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	1 June 2023
Primary completion	1 June 2025
Estimated completion	1 June 2026
Sites	1 location across China

Drugs / interventions tested

Surufatinib,Serplulimab,Etoposide,Carboplatin — full drug profile →

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Fujian Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tumour-associated macrophages: versatile players in the tumour microenvironment.
Ji ZZ, Chan MK, Chan AS, Leung KT, et al · · 2023 · cited 18× · PMID 37965573 · DOI 10.3389/fcell.2023.1261749
Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer.
Gu Y, Benavente CA. · · 2024 · cited 2× · PMID 38892831 · DOI 10.3390/jcm13113120

Verify or expand the search:

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05882630 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 31 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05882630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing